

Contents

List of Figures	11
List of Tables	12
1 Introduction	13
1.1 The kidney and acute kidney injury	13
1.1.1 Inflammatory mechanisms in AKI	14
1.1.2 AKI in intensive care	15
1.1.3 Ischemia reperfusion injury induced AKI	17
1.2 Systemic Lupus Erythematosus	18
1.2.1 Lupus Nephritis	19
1.3 Y-Box binding protein 1	20
1.3.1 Functions of extracellular YB-1	21
1.3.2 Notch-3 receptor and YB-1	22
1.4 Aim of the thesis	25
2 Materials	27
2.1 Devices	27
2.2 Consumables	29
2.3 Reagents	30
2.4 Proteins and peptides	34
2.5 Antibodies	35
2.5.1 Primary antibodies	35
2.5.2 Secondary antibodies	37
2.6 Kits	38
2.7 Cell lines	39
2.7.1 HEK293T cells	39
2.7.2 HK-2 cells	39
2.7.3 MCT cells	39
2.8 Bacteria and plasmids	40

2.9	Probes and primers	40
2.10	Software	42
3	Methods	43
3.1	Animal experiments	43
3.1.1	Mouse lines	43
3.1.2	IR surgery and antibody application	44
3.1.3	Isolation of murine bone marrow cells	46
3.1.4	ARDS mouse models	46
3.2	Microbiological methods	49
3.2.1	Heat shock transformation of <i>E. coli</i> XLI-Blue	49
3.2.2	Plasmid preparation of <i>E. coli</i> XLI-Blue	50
3.3	Cell culture methods	50
3.3.1	Cultivating of eukaryotic cells	50
3.3.2	Cell counting	50
3.3.3	Transient transfection with Lipofectamine™ 2000	51
3.3.4	Transient transfection with calcium phosphate precipitates	51
3.3.5	Cell harvest	52
3.4	Molecular biology methods	52
3.4.1	mRNA isolation	52
3.4.2	Synthesis of complementary DNA	52
3.4.3	Quantitative real-time polymerase chain reaction	52
3.5	Protein biochemical methods	54
3.5.1	Sodium dodecyl sulfate gel electrophoresis	54
3.5.2	Coomassie blue staining	55
3.5.3	Determination of protein concentration	56
3.5.4	<i>In vitro</i> guanidinylation of YB-1	56
3.5.5	Detection of post-translational guanidinylation by MALDI Mass spectro- metric analyses	56
3.5.6	Biotinylation of proteins	57
3.5.7	Receptor-ligand binding assays	57
3.5.8	Nano Differential Scanning Fluorometry	58
3.5.9	Protein isolation	58
3.6	Immunological methods	59
3.6.1	Western blot	59
3.6.2	Dot Blot	59

3.6.3	Isolation of autoantibodies against YB-1-2G with Dynabeads™ M-270 Streptavidin	60
3.6.4	Enzyme-linked immunosorbent assay	60
3.6.5	Flow cytometry	62
3.7	Histological methods	62
3.7.1	Embedding of paraffin tissue and cutting	62
3.7.2	Immunohistochemistry staining	62
3.7.3	Periodic Acid-Schiff staining	63
3.7.4	Immunofluorescence staining	64
3.8	Human sample collection, study design, and data acquisition	65
3.8.1	SLE cohorts	65
3.8.2	ARDS cohorts	65
3.9	Statistical analysis	66
4	Results	67
4.1	The role of myeloid and extracellular YB-1 in IRI	67
4.1.1	The knockout of <i>Ybx1</i> in myeloid immune cells provides a protective effect, which is negated by additional reduction of extracellular YB-1 content	67
4.1.2	Detection of anti-YB-1 antibody in tubular lumen, with a stronger signal observed in <i>Ybx1^{fl/fl}xLysM^{cre}</i> mice	73
4.1.3	<i>Ybx1^{fl/fl}xLysM^{cre}</i> mice express lower levels of CD16 receptor in dendritic cells and neutrophils	77
4.2	The role of (extracellular) YB-1 in lung-induced kidney damage	80
4.2.1	The triple-hit ARDS mouse model effectively induces inflammation and tubular damage in the secondarily affected kidney	80
4.2.2	Heterozygous <i>Ybx1</i> expression provides protection against tubular damage	82
4.2.3	Heterozygous <i>Ybx1</i> expression exacerbates inflammation in the kidneys	83
4.2.4	Intratracheal application of extracellular YB-1 triggers nephritis during mechanical ventilation	85
4.2.5	Guanidinylated extracellular YB-1 is found in ARDS mouse models and ARDS patients, and correlates with the severity of ARDS	86
4.2.6	Generation of antibodies against YB-1-2G	88
4.3	Guanidinylated YB-1 is a potential marker for LN and reflects disease activity in SLE	90
4.3.1	Serum YB-1-2G is more present in patients with LN and indicates disease activity	90
4.3.2	Serum YB-1-2G is a more effective biomarker for LN than urine YB-1-2G	93

4.3.3	Establishment of a YB-1-2G ELISA	94
4.3.4	Autoantibodies against guanidinylated YB-1 in MRL. <i>lpr</i> mouse model and SLE/LN patients	99
4.4	Molecular basis and binding capabilities of guanidinylated YB-1	106
4.4.1	Overexpression of GATM in tubular cells leads to elevated secretion and guanidinylation of YB-1	106
4.4.2	Urea may contribute to guanidinylation of YB-1 <i>in vitro</i>	108
4.4.3	YB-1 and YB-1-2G exhibit equal binding affinity to Notch-3 and compete with the canonical ligand Jagged-1	108
4.4.4	YB-1 exhibits higher thermal stability than YB-1-G	111
5	Discussion	113
5.1	Dual roles of myeloid YB-1 in IRI	113
5.2	YB-1 as therapeutic target in lung-induced kidney damage	116
5.3	YB-1-2G as a disease marker	118
5.4	Structural and functional impact of YB-1 guanidinylation	120
6	Summary	123
	Bibliography	127
	List of Abbreviations	151
	Danksagung	153